DIAMEDICA THERAP (DMAC)
$3.78
0.01 (0.26%)
DMAC Stock Earnings: DiaMedica Therapeutics Beats EPS for Q2 2024
DMAC stock results show that DiaMedica Therapeutics beat analyst estimates for earnings per share the second quarter of 2024.

Louis Navellier's Total Grade
Powered by Portfolio Grader?
Unlock Louis Navellier's
? Stock Report – FREE:

Is ? a BUY?
Powered by Portfolio Grader
A
B
C
D
F
?
Unlock Louis Navellier's
? Stock Report to Find Out – FREE:

Louis Navellier's Total Grade
Powered by Portfolio Grader?
Investing legend Louis Navellier rates ? a "?." Unlock his ? Stock Analysis to find out why – FREE:

Louis Navellier's Total Grade
Powered by Portfolio Grader?
Fundamental Grade
Quantitative Grade
- Sales Growth ?
- Operating Margin Growth ?
- Earnings Growth ?
- Earnings Momentum ?
- Earnings Surprises ?
- Analyst Earnings Revisions ?
- Cash Flow ?
- Return on Equity ?
Previous Close
$3.82
Market Cap
163.71M
PE Ratio
-6.24
EPS
-0.6053
Volume (Avg. Vol.)
92,361
Day's Range
$3.62 - $3.84
52-Week Range
$2.14 - $6.82
Dividend & Yield
N/A (N/A)